Microvessel and Lymphatic Vessel Density and VEGFR-3 Expression of Papillary Thyroid Carcinoma with Comparative Analysis of Clinicopathological Characteristics
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background : This study was done to see if there were correlations between anatomic and molecular parameters such as microvessel density (MVD), lymphatic vessel density (LVD), and vascular endothelial growth factor receptor (VEGFR)-3 expression and various clinical parameters for papillary thyroid carcinomas of size > 1.0 cm (PTCs) and size ≤ 1.0 cm (papillary thyroid microcarcinomas, PTMCs). PTMCs were divided into two subgroups (0-5 mm and 6-10 mm). Methods : We analyzed 197 thyroid carcinomas including 113 PTCs and 84 PTMCs. Tissue samples form 30 patients from each group matched for clinical characteristics were selected for immunostaining. Results : Although PTCs and PTMCs showed significant differences in clinical characteristics, they did not show significant difference in MVD, LVD, or VEGFR-3 expression. There was a significantly higher LVD in the PTMC subgroup with the larger tumors but no difference in clinical characteristics. LVD was higher in patients > 45 years old (more apparent in the PTC group) and LVD had suggestive correlations with multicentricity and extrathyroidal extension depending on analytic conditions. Conclusions : Since LVD showed variable correlations with clinical variables for papillary carcinoma of the thyroid depending on analytic conditions, the individually planned treatments based on overall clinicopathological factors are advised.
Abstract
Background : This study was done to see if there were correlations between anatomic and molecular parameters such as microvessel density (MVD), lymphatic vessel density (LVD), and vascular endothelial growth factor receptor (VEGFR)-3 expression and various clinical parameters for papillary thyroid carcinomas of size > 1.0 cm (PTCs) and size ≤ 1.0 cm (papillary thyroid microcarcinomas, PTMCs). PTMCs were divided into two subgroups (0-5 mm and 6-10 mm). Methods : We analyzed 197 thyroid carcinomas including 113 PTCs and 84 PTMCs. Tissue samples form 30 patients from each group matched for clinical characteristics were selected for immunostaining. Results : Although PTCs and PTMCs showed significant differences in clinical characteristics, they did not show significant difference in MVD, LVD, or VEGFR-3 expression. There was a significantly higher LVD in the PTMC subgroup with the larger tumors but no difference in clinical characteristics. LVD was higher in patients > 45 years old (more apparent in the PTC group) and LVD had suggestive correlations with multicentricity and extrathyroidal extension depending on analytic conditions. Conclusions : Since LVD showed variable correlations with clinical variables for papillary carcinoma of the thyroid depending on analytic conditions, the individually planned treatments based on overall clinicopathological factors are advised.
참고문헌 (30)
- Pellegriti G, "Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter:study of 299 cases", J Clin Endocrinol Metab, 89, pp.3713~3720 (2004)
- 이잔디, "유두 미세 갑상선암: 임상병리적 특성과 치료전략", 대한외과학회지, 72(4), pp.276~282 (2007), 대한외과학회
- Lee J, "Frequent,aggressive behaviors of thyroid microcarcinomas in Korean patients", Endocr J, 53, pp.627~632 (2006)
- Kim TY, "Prognostic parameters for recurrence of papillary thyroid microcarcinoma", BMC Cancer, 8, pp.296~ (2008)
- Roti E, "Clinical and histological characteristics of papillary thyroid microcarcinoma:results of a retrospective study in 243 patients", J Clin Endocrinol Metab, 91, pp.2171~2178 (2006)
- Chow SM, "Papillary microcarcinoma of the thyroid:prognostic significance of lymph node metastasis and multifocality", Cancer, 98, pp.31~40 (2003)
- He Y, "Role of lymphangiogenic factors in tumor metastasis", Biochlm Biophys Acta, 1654, pp.3~12 (2004)
- Stacker SA, "Lymphangiogenic growth factors as markers of tumor metastasis", APMIS, 112, pp.539~549 (2004)
- Yasuoka H, "VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma", Mod Pathol, 18, pp.1127~1133 (2005)
- de la Torre NG, "Angiogenesis and lymphangiogenesis in thyroid proliferative lesions:relationship to type and tumour behaviour", Endocr Relat Cancer, 13, pp.931~944 (2006)
- Liang QC, "Expression of VEGF-C and angiogenesis, and lymphangiogenesis in papillary thyroid carcinoma", Zhong Nan Da Xue Xue Bao Yi Xue Ban, 31, pp.414~419 (2006)
- Siironen P, "VEGF-C and COX-2 expression in papillary thyroid cancer", Endocr Relat Cancer, 13, pp.465~473 (2006)
- Klein M, "Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma", J Clin Endocrinol Metab, 86, pp.656~658 (2001)
- Jebreel A, "Vascular endothelial growth factor(VEGF),VEGF receptors expression and microvascular density in benign and malignant thyroid diseases", Int J Exp Pathol, 88, pp.271~277 (2007)
- Shushanov S, "VEGFc and VEGFR3 expression in human thyroid pathologies", Int J Cancer, 86, pp.47~52 (2000)
- Yu XM, "Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases", Clin Cancer Res, 11, pp.8063~8069 (2005)
- Wong NA, "Measurement of vascularity as a diagnostic and prognostic tool for well differentiated thyroid tumours:comparison of different methods of assessing vascularity", J Clin Pathol, 52, pp.593~597 (1999)
- Besic N, "Papillary thyroid microcarcinoma:prognostic factors and treatment", J Surg Oncol, 97, pp.221~225 (2008)
- Siironen P, "Prognostic factors in papillary thyroid cancer:an evaluation of 601 consecutive patients", Tumour Biol, 26, pp.57~64 (2005)
- Harach HR, "Occult papillary carcinoma of the thyroid:a"normal"finding in Finland.A systematic autopsy study", Cancer, 56, pp.531~538 (1985)
- Akslen LA, "Increased angiogenesis in papillary thyroid carcinoma but lack of prognostic importance", Hum Pathol, 31, pp.439~442 (2000)
- Bunone G, "Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features", Am J Pathol, 155, pp.1967~1976 (1999)
- Dhar DK, "Tumor vascularity predicts recurrence in differentiated thyroid carcinoma", Am J Surg, 176, pp.442~447 (1998)
- Goldenberg JD, "Well-differentiated thyroid carcinomas:p53 mutation status and microvessel density", Head Neck, 20, pp.152~158 (1998)
- Fontanini G, "Microvessel count:an indicator of poor outcome in medullary thyroid carcinoma but not in other types of thyroid carcinoma", Mod Pathol, 9, pp.636~641 (1996)
- Herrmann G, "T lymphocytes,CD68-positive cells and vascularisation in thyroid carcinomas", J Cancer Res Clin Oncol, 120, pp.651~656 (1994)
- Padera TP, "Lymphatic metastasis in the absence of functional intratumor lymphatics", Science, 296, pp.1883~1886 (2002)
- Hall FT, "Intratumoral lymphatics and lymph node metastases in papillary thyroid carcinoma", Arch Otolaryngol Head Neck Surg, 129, pp.716~719 (2003)
- Cushing SL, "Prognostic factors in well-differentiated thyroid carcinoma", Laryngoscope, 114, pp.2110~2115 (2004)
- Jung TS, "Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma", Endocr J, 54, pp.265~274 (2007)